Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
Key result
Dapagliflozin shortens time to clinical benefit in HFrEF compared to those with prior HF hospitalization.
Authors
Discussion
Loading...
Member takes
Implication
Supports early dapagliflozin initiation in HFrEF; extends RCT evidence on rapid time to benefit.
Key Points
- To assess the time to clinical benefit of dapagliflozin in patients with heart failure with reduced ejection fraction and the role of prior hospitalization due to heart failure.
- Randomized controlled trial design
- Inclusion of patients with reduced ejection fraction
- Administration of dapagliflozin
- Assessment of clinical outcomes over time
- Dapagliflozin showed a significant time to clinical benefit
- Prior heart failure hospitalization influenced outcomes
- Improvement in clinical markers of heart failure noted
Cite This Study
Berg et al. (2021) studied this question. Dapagliflozin significantly shortened the time to clinical benefit in patients with heart failure with reduced ejection fraction compared to those with prior hospitalization for heart failure.